Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
Open Access
- 7 January 2009
- journal article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 7 (1), 2
- https://doi.org/10.1186/1479-5876-7-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapyBritish Journal of Cancer, 2005
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancerBiochemical Journal, 2002
- Interleukin-2: Clinical applicationsSeminars in Oncology, 2002
- Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?1998
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2Annals of Surgery, 1998
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaNature Medicine, 1998
- 5T4 oncofetal antigen expression in ovarian carcinomaInternational Journal of Gynecologic Cancer, 1995
- Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinomaBritish Journal of Cancer, 1994
- The expression of 5T4 antigen in colorectal and gastric carcinomaBritish Journal of Cancer, 1992